Predictions
Innate Pharma
Start price
Target price
Perf. (%)
€4.10
15.11.20
15.11.20
€5.50
15.11.21
15.11.21
7.86%
16.11.21
16.11.21
Could be worthwhile Investment >10% per year
Aphria Inc.
Start price
Target price
Perf. (%)
€4.90
14.11.20
14.11.20
-
14.11.21
14.11.21
23.24%
27.11.20
27.11.20
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Standard Investments for future growth
High dividend yield expected
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€51.30
14.11.20
14.11.20
-
14.11.21
14.11.21
-1.75%
23.11.20
23.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Enzon Pharmaceuticals
Start price
Target price
Perf. (%)
€0.10
14.11.20
14.11.20
-
14.11.21
14.11.21
120.00%
14.01.21
14.01.21
Risky Investment
Nicheplayer
Higher risks for its business
Horizon Pharma plc
Start price
Target price
Perf. (%)
€61.15
13.11.20
13.11.20
-
13.11.21
13.11.21
30.20%
15.07.21
15.07.21
Could be very worthwhile Investment >20% year
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€50.60
13.11.20
13.11.20
€52.00
1.38%
14.11.20
14.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Fresenius SE & Co. KGaA
Start price
Target price
Perf. (%)
€36.97
12.11.20
12.11.20
€50.00
12.11.21
12.11.21
21.49%
13.07.21
13.07.21
Top 10 in its market
Small cyclical dependencies
Below average Management
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€50.00
09.11.20
09.11.20
€55.00
2.66%
10.11.20
10.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Pfizer Inc.
Start price
Target price
Perf. (%)
€33.30
09.11.20
09.11.20
€37.95
-11.94%
17.12.20
17.12.20
Capable Management
Good culture
Innovative
Differentiated customer and product portfolio
Fresenius SE & Co. KGaA
Start price
Target price
Perf. (%)
€34.41
09.11.20
09.11.20
€40.00
09.11.21
09.11.21
18.27%
02.11.21
02.11.21
Could be very worthwhile Investment >20% year
Market Leader or Top 3
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Bellicum Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.30
07.11.20
07.11.20
-
07.11.21
07.11.21
15.65%
15.07.21
15.07.21
Probably not worthwhile Investment
WAVE Life Sciences Ltd
Start price
Target price
Perf. (%)
€5.80
07.11.20
07.11.20
-
07.11.21
07.11.21
-0.34%
15.07.21
15.07.21
Could be very worthwhile Investment >20% year
Aphria Inc.
Start price
Target price
Perf. (%)
€5.20
07.11.20
07.11.20
€6.40
23.49%
30.11.20
30.11.20
Could be worthwhile Investment >10% per year
Very Future proof/growth oriented business model
Revenue growth >5% per year expected
Ose Pharma International S.A.
Start price
Target price
Perf. (%)
€9.36
06.11.20
06.11.20
€14.00
06.11.21
06.11.21
23.50%
21.09.21
21.09.21
Could be worthwhile Investment >10% per year
Aphria Inc.
Start price
Target price
Perf. (%)
€4.70
05.11.20
05.11.20
-
05.11.21
05.11.21
170.32%
06.11.21
06.11.21
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
CytoDyn Inc_INT
Start price
Target price
Perf. (%)
€2.26
04.11.20
04.11.20
€3.20
04.11.21
04.11.21
-43.45%
10.07.21
10.07.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Significant cyclical dependencies
WAVE Life Sciences Ltd
Start price
Target price
Perf. (%)
€6.40
04.11.20
04.11.20
-
-9.38%
07.11.20
07.11.20
Could be very worthwhile Investment >20% year
Bio-Gate AG
Start price
Target price
Perf. (%)
€5.90
04.11.20
04.11.20
-
04.11.21
04.11.21
-32.20%
05.11.21
05.11.21
Growths faster than the competition
Few uniques
Dependend from some customers or products
Probably not worthwhile Investment
BioLine RX Ltd ADR
Start price
Target price
Perf. (%)
€2.46
03.11.20
03.11.20
€3.50
04.11.21
04.11.21
-4.88%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
DBV Technologies S.A.
Start price
Target price
Perf. (%)
€3.45
03.11.20
03.11.20
-
04.11.21
04.11.21
136.51%
15.01.21
15.01.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
DBV Technologies S.A.
Start price
Target price
Perf. (%)
€3.53
03.11.20
03.11.20
€10.50
04.11.21
04.11.21
51.47%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Humana Inc.
Start price
Target price
Perf. (%)
€364.00
03.11.20
03.11.20
-
04.11.21
04.11.21
-6.04%
14.01.21
14.01.21
Could be worthwhile Investment >10% per year
Differentiated customer and product portfolio
Higher risks for its business
Misonix Inc.
Start price
Target price
Perf. (%)
€9.55
02.11.20
02.11.20
€11.00
04.11.21
04.11.21
4.19%
16.11.20
16.11.20
Could be worthwhile Investment >10% per year